Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL BaSyc is ...

In traditional schedule or dose–schedule finding designs, patients are assumed to receive their assigned dose–schedule combination throughout the trial even though the combination may be found to have ...

Relationship between overall survival and progression-free survival for recent NCCTG glioblastoma multiforme trials. Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate ...

The US Food and Drug Administration (FDA) on Friday unveiled two draft guidances focused on adaptive clinical trial designs and master protocols for cancer treatment trials. The 32-page adaptive ...

Health care is undergoing an important and well-needed shift from a one-size-fits-all approach to more personalized, precise, patient-focused care. A similar approach needs to be implemented at scale ...